References
- Chalumeau M, Tréluyer JM, Salanave B, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child. 2000;83(6):502–505.
- Ekins-Daukes S, Helms PJ, Simpson CR, et al. Off-label prescribing to children in primary care: retrospective observational study. Eur J Clin Pharmacol. 2004; 60(5):349–353.
- 9th European Conference on Rare Diseases & Orphan Products (ECRD Vienna 2018). Orphanet J Rare Dis. 2018;13:167.
- Weda M, Hoebert J, Vervloet M, et al. Study on off-label use of medicinal products in the European Union. European Commission. 2017. Available from: https://op.europa.eu/en/home
- Drenska M, Grigorova V, Elitova S, et al. The off-label use of medicines in pediatric outpatients in Bulgaria based on an analysis of their prescription data. Drugs Ther Perspect. 2019;35(8):391–395.
- Drenska M, Elitova S, Grigorova V, et al. Analysis of primary outpatient data for off-label use of medicines in neurology. PHAR. 2019;66(4):165–170.
- Council of the European Union. Directive 2001/83/EU of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. 2001; OJ L 311, 28.112001; p. 67–128. Available from: https://ec.europa.eu/health/documents/eudralex/vol-1_en
- Council of the European Union. Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency. 2004. OB L 136, 30.04.2004; p. 1–33. Available from: https://ec.europa.eu/health/documents/eudralex/vol-1_en
- Sotirova Y, Issaev S, Grigorov E. Possibilities for conducting treatment with unauthorized medicinal products in Bulgaria. Ann Hosp Pharm. 2020;6(1):49–57.
- Degrassat-Théas A, Bocquet F, Sinègre M, et.al. The "temporary recommendations for use": a dual-purpose regulatory framework for off-label drug use in France. Health Policy. 2015;119(11):1399–1405.
- Prada М, Bertozzi C, Proietti B, et al. The Italian 648/96 list: approvals, rejections and methods in Aifa’s evaluation process between January 2013 and May 2015. Value Health. 2015;18(7):A680.
- Faus J, Moliner X, Suarez J, et al. Medicinal product regulation and product liability in Spain: overview. [Web Page]. Thomson Reuters - Practical Law; 2018. Available from: https://uk.practicallaw.thomsonreuters.com/8-500-4409?navId=8EC5F403350E364FC5BAEE5763E7F8FE&comp=pluk&transitionType=Default&contextData=%28sc.Default%29
- Obermann S. Off-Label Use of Medicines – General Aspects, Challenges and Strategies. PhD Thesis. Bonn: Angefertigt mit Genehmigung der Mathematisch-Naturwissenschaftlichen Fakultät der Rheinischen Friedrich-Wilhelms-Universität Bonn; 2013. Available from: https://dgra.de/deutsch/studiengang/master-thesis/2013-9075
- General Medical Council (GMC). Prescribing and managing medicines and devices. [Revised 2019]. GMC; 2013. Available from: https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/prescribing-and-managing-medicines-and-devices
- Law on Medicinal Products in Human Medicine. Bulgaria. SG. 31/13 April 2007, amend and suppl. SG. 67/28 Jul 2020. Available from: https://dv.parliament.bg
- Drenska M, Getov I. Research on approaches for regulation of the "off-label" use of medicinal products in the European Union. Acta Medica Bulg. 2017;44(1):17–21.
- Pérez RP, Antorán MR, Solá CA, et al. Results from the 2012-2013 paediatric national survey on off-label drug use in children in Spain (OL-PED study). An Pediatr (Barc). 2014;81(1):16–21.
- Hagemann V, Bausewein C, Rémi C. Off-label-prescriptions in daily clinical practice – a cross-sectional national survey of palliative medicine physicians. Prog Palliat Care. 2019;27(4):154–159.
- Drenska M, Naseva E, Getov I. The knowledge and experience with the off-label use – results of a survey. Pharmacia 2019;66(4):217–221.
- Saullo F, Saullo E, Caloiero M, et al. A questionnaire-based study in Calabria on the knowledge of off-label drugs in pediatrics. J Pharmacol Pharmacother. 2013;4(Suppl 1):S51–S54.